Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 16

  • 956 clinical trials
  • 393 recruiting
  • 345 conditions
  • 28 countries

Conditions in this area

345 conditions with trials, the busiest first

Breast cancer168Prostate cancer101Ovarian cancer91Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer41Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer18Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+321

Clinical trials in Reproductive system and breast disorders

956 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

956 clinical trials

Hormone-refractory prostate cancer+1

Recruiting

Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Triple negative breast cancer

Recruiting

Study of Atezolizumab, Carboplatin, and Nab-Paclitaxel for Patients with Metastatic Triple-Negative PD-L1 Positive Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Consorzio Oncotech

Breast cancer

Recruiting

Study on Low-Dose Gadolinium for Breast Cancer MRI in Patients Using Gadoteric Acid

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Gadoteric Acid
  • Sponsor:Stichting Radboud University Medical Center

Prostate cancer metastatic

Recruiting

Study of 177Lu-PSMA and Stereotactic Radiotherapy vs. Radiotherapy for Patients with Oligometastatic Prostate Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:177LU-PSMA-I&T
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Peyronie's disease

Recruiting

Study on the Safety and Effectiveness of Vibrio Alginolyticus Collagenase and Alprostadil for Patients with Peyronie's Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ALPROSTADIL
  • Sponsor:Fidia Farmaceutici S.p.A.

Prostate cancer

Recruiting

Study on Lutetium (177Lu) Zadavotide Guraxetan for Prostate Cancer Patients with Biochemical Recurrence After Initial Curative Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Medical University Of Vienna

Peyronie's disease

Recruiting

Study on the Use of FAPI-PET/CT and FDG-PET/CT Scans for Detecting Active Fibroblasts and Inflammation in Patients with Acute Phase Peyronie's Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Universitair Medisch Centrum Groningen

Triple negative breast cancer

Recruiting

Study of Datopotamab Deruxtecan for Patients with Triple-Negative Breast Cancer and New or Worsening Brain Metastases

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Datopotamab Deruxtecan
  • Sponsor:Medical University Of Vienna

Infertility female

Recruiting

Study on the Effect of Metformin on Endometrial Function in Women with Unexplained Infertility

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Metformin Hydrochloride
  • Sponsor:Agencja Badań Medycznych

Hormone-refractory prostate cancer

Recruiting

Study Comparing Docetaxel and Androgen Receptor-Targeted Agents (Abiraterone or Enzalutamide) for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Vulval cancer recurrent

Recruiting

Study on Electrochemotherapy with Carboplatin and Bleomycin for Women with Relapsed Vulvar Cancer After Multiple Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico

Hormone-refractory prostate cancer

Recruiting

Study of Ebastine and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients with Advanced Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cabazitaxel
  • Sponsor:Region Hovedstaden

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab77 clinical trialsLetrozole73 clinical trialsFulvestrant58 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane46 clinical trialsAnastrozole44 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.